3人のアペリスの内部関係者は 1月20日に10万7千ドルの株を売り上げました 強い利益と株価上昇のなかです 
Three Apellis insiders sold $107K in stock Jan. 20 amid strong earnings and rising shares.
2026年1月20日,アペリス製薬の3人の内部関係者Nur Nicholson,James George Chopas,David Watsonは,合計5,404株を平均株価19.79ドルで販売し,合計約106,945ドルとなった. On January 20, 2026, three Apellis Pharmaceuticals insiders—Nur Nicholson, James George Chopas, and David Watson—sold a combined total of 5,404 shares at an average price of $19.79 per share, totaling approximately $106,945. SECの書類に記載された取引により,ニコルソンの所有権は78,843株,ワトソンの所有権は96,363株に減った. The transactions, disclosed in SEC filings, reduced their ownership stakes, with Nicholson’s holding dropping to 78,843 shares and Watson’s to 96,363. 株価は平均より高い取引量で1月21日に20.95ドルで閉店し,0.48ドル上昇した. The company’s stock closed at $20.95 on January 21, up $0.48, with above-average trading volume. アペリスは10月30日に強な第3四半期利益を報告し,EPS1.67ドルを記録し,推定値0.64ドルを上回り,同年比133%の収益増加を記録した. Apellis reported strong Q3 earnings on October 30, posting $1.67 EPS, surpassing estimates by $0.64, and recording a 133% year-over-year revenue increase. 同社は,まれな疾病療法に焦点をあて,市場資本は265億円で,同社は3. 3.53の目標に掲げる"モデレード・バイヤー"の評価を表明している. The company, focused on rare disease therapies, has a market cap of $2.65 billion and a consensus “Moderate Buy” rating with a target of $33.53.
